LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 3 of total 3

Search options

  1. Article ; Online: Author Correction: Locoregional delivery of IL-13Rα2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial.

    Brown, Christine E / Hibbard, Jonathan C / Alizadeh, Darya / Blanchard, M Suzette / Natri, Heini M / Wang, Dongrui / Ostberg, Julie R / Aguilar, Brenda / Wagner, Jamie R / Paul, Jinny A / Starr, Renate / Wong, Robyn A / Chen, Wuyang / Shulkin, Noah / Aftabizadeh, Maryam / Filippov, Aleksandr / Chaudhry, Ammar / Ressler, Julie A / Kilpatrick, Julie /
    Myers-McNamara, Paige / Chen, Mike / Wang, Leo D / Rockne, Russell C / Georges, Joseph / Portnow, Jana / Barish, Michael E / D'Apuzzo, Massimo / Banovich, Nicholas E / Forman, Stephen J / Badie, Behnam

    Nature medicine

    2024  

    Language English
    Publishing date 2024-03-21
    Publishing country United States
    Document type Published Erratum
    ZDB-ID 1220066-9
    ISSN 1546-170X ; 1078-8956
    ISSN (online) 1546-170X
    ISSN 1078-8956
    DOI 10.1038/s41591-024-02928-5
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4212: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MG 39: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Locoregional delivery of IL-13Rα2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial.

    Brown, Christine E / Hibbard, Jonathan C / Alizadeh, Darya / Blanchard, M Suzette / Natri, Heini M / Wang, Dongrui / Ostberg, Julie R / Aguilar, Brenda / Wagner, Jamie R / Paul, Jinny A / Starr, Renate / Wong, Robyn A / Chen, Wuyang / Shulkin, Noah / Aftabizadeh, Maryam / Filippov, Aleksandr / Chaudhry, Ammar / Ressler, Julie A / Kilpatrick, Julie /
    Myers-McNamara, Paige / Chen, Mike / Wang, Leo D / Rockne, Russell C / Georges, Joseph / Portnow, Jana / Barish, Michael E / D'Apuzzo, Massimo / Banovich, Nicholas E / Forman, Stephen J / Badie, Behnam

    Nature medicine

    2024  Volume 30, Issue 4, Page(s) 1001–1012

    Abstract: Chimeric antigen receptor T cell (CAR-T) therapy is an emerging strategy to improve treatment outcomes for recurrent high-grade glioma, a cancer that responds poorly to current therapies. Here we report a completed phase I trial evaluating IL-13Rα2- ... ...

    Abstract Chimeric antigen receptor T cell (CAR-T) therapy is an emerging strategy to improve treatment outcomes for recurrent high-grade glioma, a cancer that responds poorly to current therapies. Here we report a completed phase I trial evaluating IL-13Rα2-targeted CAR-T cells in 65 patients with recurrent high-grade glioma, the majority being recurrent glioblastoma (rGBM). Primary objectives were safety and feasibility, maximum tolerated dose/maximum feasible dose and a recommended phase 2 dose plan. Secondary objectives included overall survival, disease response, cytokine dynamics and tumor immune contexture biomarkers. This trial evolved to evaluate three routes of locoregional T cell administration (intratumoral (ICT), intraventricular (ICV) and dual ICT/ICV) and two manufacturing platforms, culminating in arm 5, which utilized dual ICT/ICV delivery and an optimized manufacturing process. Locoregional CAR-T cell administration was feasible and well tolerated, and as there were no dose-limiting toxicities across all arms, a maximum tolerated dose was not determined. Probable treatment-related grade 3+ toxicities were one grade 3 encephalopathy and one grade 3 ataxia. A clinical maximum feasible dose of 200 × 10
    MeSH term(s) Humans ; Receptors, Chimeric Antigen ; Neoplasm Recurrence, Local ; Glioma/therapy ; T-Lymphocytes ; Glioblastoma/therapy ; Immunotherapy, Adoptive/adverse effects ; Immunotherapy, Adoptive/methods
    Chemical Substances Receptors, Chimeric Antigen
    Language English
    Publishing date 2024-03-07
    Publishing country United States
    Document type Clinical Trial, Phase I ; Journal Article
    ZDB-ID 1220066-9
    ISSN 1546-170X ; 1078-8956
    ISSN (online) 1546-170X
    ISSN 1078-8956
    DOI 10.1038/s41591-024-02875-1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4212: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MG 39: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article: Expansion of endogenous T cells in CSF of pediatric CNS tumor patients undergoing locoregional delivery of IL13R〿2-targeting CAR T cells: an interim analysis.

    Wang, Leo / Oill, Angela Taravella / Blanchard, M / Wu, Melody / Hibbard, Jonathan / Sepulveda, Sean / Peter, Lance / Kilpatrick, Julie / Munoz, Margarita / Stiller, Tracey / Shulkin, Noah / Wagner, Jamie / Dolatabadi, Ally / Nisis, Monica / Shepphird, Jennifer / Sanchez, Gabriela / Lingaraju, Chetan / Manchanda, Mishika / Natri, Heini /
    Kouakanou, Léonce / Sun, Grace / Oliver-Cervantes, Cheryl / Georges, Joseph / Aftabizadeh, Maryam / Forman, Stephen / Priceman, Saul / Ressler, Julie / Arvanitis, Leonidas / Cotter, Jennifer / D'Apuzzo, Massimo / Tamrazi, Benita / Badie, Behnam / Davidson, Tom / Banovich, Nicholas / Brown, Christine

    Research square

    2023  

    Abstract: Outcomes for pediatric brain tumor patients remain poor, and there is optimism that chimeric antigen receptor (CAR) T cell therapy can improve prognosis. Here, we present interim results from the first six pediatric patients treated on an ongoing phase I ...

    Abstract Outcomes for pediatric brain tumor patients remain poor, and there is optimism that chimeric antigen receptor (CAR) T cell therapy can improve prognosis. Here, we present interim results from the first six pediatric patients treated on an ongoing phase I clinical trial (NCT04510051) of IL13BBζ-CAR T cells delivered weekly into the lateral cerebral ventricles, identifying clonal expansion of endogenous CAR-negative CD8
    Language English
    Publishing date 2023-10-23
    Publishing country United States
    Document type Preprint
    DOI 10.21203/rs.3.rs-3454977/v1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top